Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 5/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 5/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526571 | 0.84 | NMT2 (0.44) | KDM4EKCNH2HRH3ESR1ESR2 | |
| SCHEMBL10593191 | 0.73 | PTPN1 (0.50) | KDM4EKCNH2HRH3NMT2NMT1 | |
| Hydrochloric Acid SCHEMBL10527368 | 0.72 | PTPN1 (0.49) | KDM4EKCNH2HRH3NMT2NMT1 | |
| SCHEMBL9788513 | 0.69 | NMT2 (0.47) | KDM4EKCNH2HRH3ESR1ESR2 | |
| SCHEMBL10390759 | 0.69 | IRAK4 (0.49) | — | |
| SCHEMBL9788511 | 0.69 | ALDH1A1 (0.52) | KDM4ENMT2NMT1 | |
| SCHEMBL228881 | 0.68 | KCNH2 (0.81) | KDM4EKCNH2HRH3ESR1ESR2 | |
| SCHEMBL223800 | 0.68 | KCNH2 (0.81) | KDM4EKCNH2HRH3ESR1ESR2 | |
| SCHEMBL21408440 | 0.68 | KDM4E (0.61) | KDM4EKCNH2HRH3ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL9788506 | 0.68 | NMT2 (0.46) | KDM4EKCNH2HRH3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347932-A2 | Treatment of conditions requiring enhanced oxygen availability to mammalian tissues | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-27 | — | — | EP | claimed |